⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

January 17, 2026International Journal of Clinical Oncology

Efficacy and safety of bevacizumab-combined single-agent chemotherapy for platinum-resistant ovarian cancer that recurred during PARP inhibitor treatment

Eriko Takatori T SHOJI Ami Jo Miku Musashi Shunsuke Tatsuki Nanako Jonai YOHEI CHIBA Sho Sato Yoshitaka Kaido Takayuki Nagasawa Masahiro Kagabu Fumiaki Takahashi Takeshi Aida Tsukasa Baba

View at Publisher

Ask AI

Bookmark

Share

Key Points

Response noted in platinum-resistant ovarian cancer across 40 patients, demonstrating a notable efficacy with bevacizumab.
49% of patients showed partial or complete response to the treatment, indicating a significant impact.
Observational analysis of treatment combining bevacizumab with single-agent chemotherapy.
Findings highlight the promise of this combination therapy, but results must be validated in larger, controlled trials.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Observational analysis reveals improved tumor response in patients with platinum-resistant ovarian cancer, suggesting potential treatment benefits.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Takatori et al. (2026) studied this question.

synapsesocial.com/papers/69a759ecc6e9836116a1f50f https://doi.org/10.1007/s10147-026-02959-7

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using <scp>GLOBOCAN</scp> 2020Original Research · 2022 · 309 citations
2Cancer statistics, 2024Registry Study · 2024 · 10,495 citations
3Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group StudyLate-Phase Clinical Trial · 2003 · 2,052 citations
4Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 TrialCohort Study · 2022 · 503 citations
5Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trialOriginal Research · 2023 · 421 citations
6Niraparib in Patients with Newly Diagnosed Advanced Ovarian CancerRCT · 2019 · 2,330 citations
7Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian CancerRCT · 2023 · 166 citations
8PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancerRetrospective Study · 2021 · 24 citations
9Prognostic impact of surgical resection after chemotherapy in oligometastatic versus non-oligometastatic gastric cancerInternational Journal of Clinical Oncology · 2026
10Interstitial lung disease in patients with recurrent and metastatic head and neck cancer treated with immune checkpoint inhibitors and cetuximab and/or paclitaxelInternational Journal of Clinical Oncology · 2026

More from International Journal of Clinical Oncology

More from Iwate Medical University

More from Japanese Red Cross Hadano Hospital